Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.In a statement, Health ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Kenya has been selected as one of the 9 early adopter countries for the rollout of Lenacapavir (LEN), a long-acting ...

Lenacapavir, which was approved by the United States' Food and Drug Administration in June this year, is taken twice per year ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...